Barr ciprofloxacin marketing continues
Executive Summary
Barr will continue to market authorized generic of Bayer's antibiotic Cipro (ciprofloxacin) during the product's expected pediatric exclusivity, which runs for six months beginning Dec. 9, under an amended agreement. Barr had a similar deal on AstraZeneca's breast cancer drug Nolvadex (tamoxifen) but was forced to drop its authorized generic during the pediatric exclusivity period (1"The Pink Sheet" Feb. 3, 2003, p. 13)...